Comparative sequence analysis of the VHL tumor suppressor gene

Genomics

Volumn 65, Issue 3, 2000, Pages 253-265

  Woodward, Emma R ^a   Buchberger, Alexander ^b   Clifford, Steven C ^c   Hurst, Laurence D ^d   Affara, Nabeel A ^a   Maher, Eamonn R ^c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^d UNIVERSITY OF BATH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRONECTIN; GENE PRODUCT; TRANSCRIPTION FACTOR SP1;

ARTICLE; CAENORHABDITIS ELEGANS; COMPARATIVE STUDY; GENE MUTATION; GENE SEQUENCE; GENETIC CONSERVATION; HUMAN; MOLECULAR EVOLUTION; NONHUMAN; PRIMATE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RNA TRANSLATION; RODENT; SEQUENCE ANALYSIS; SPECIES DIFFERENCE; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE;

EID: 0034192719     PISSN: 08887543     EISSN: None     Source Type: Journal    
DOI: 10.1006/geno.2000.6144     Document Type: Article

References (42)

1. Ahringer J. Turn to the worm! Curr. Opin. Genet. Dev. 7:1997;410-415.
2. Brauch H., Kishida T., Glavac D., Chen F., Pausch F., Hofler H., Latif F. von Hippel Lindau disease with pheochromocytoma in the Black Forest region of Germany: Evidence for a founder effect. Hum. Genet. 95:1995;551-556.
3. Chen F., Kishida T., Yao M., Hustad T., Glavac D., Dean M., Gnarra J. R., Orcutt M. L., Duh F. M., Glenn G., Green J., Hsia E., Lamiell J., Li H., Wei M. H., Schmidt L., Tory K., Kuzmin I., Stackhouse T., Latif F., Linehan W. M., Lerman M., Zbar B. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: Correlations with phenotype. Hum. Mutat. 5:1995;66-75.
4. Clifford S. C., Walsh S., Hewson K., Brinke A., Green P. M., Gianelli F., Pause A., Eng C., Maher E. R. Genomic structure and chromosomal localisation of the human CUL2 gene and mutation analysis of von Hippel-Lindau tumour suppressor-associated proteins (CUL2 and VBP-1) in renal cell carcinoma. Genes Chromosomes Cancer. 26:1999;20-28.
5. Comeron J. M. A methods for estimating the numbers of synonymous and nonsynonymous substitutions per site. J. Mol. Evol. 41:1995;1152-1159.
6. Crossey P. A., Eng C., Ginalska-Malinowska M., Lennard T. W. J., Sampson J. R., Ponder B. A. J., Maher E. R. Molecular genetic diagnosis of von Hippel-Lindau disease in familial phaeochromocytoma. J. Med. Genet. 32:1995;885-886.
7. Crossey P. A., Richards F. M., Foster K., Green J. S., Prowse A., Latif F., Lerman M. I., Zbar B., Affara N. A., Ferguson-Smith M. A., Maher E. R. Identification of intragenic mutations in the von Hippel-Lindau disease tumor suppressor gene and correlation with disease phenotype. Hum. Mol. Genet. 3:1994;1303-1308.
8. Duan D. R., Humphrey J. S., Chen D. Y. T., Weng Y., Sukegawa J., Lee S., Gnarra J. R., Linehan W. M., Klausner R. D. Characterization of the VHL tumour suppressor gene product: Localization, complex formation, and the effect of natural inactivating mutations. Proc. Natl. Acad. Sci. USA. 92:1995;6495-6499.
9. Duan D. R., Pause A., Burgress W., Aso T., Chen D. Y. T., Garrett K. P., Conaway R. C., Conaway J. W., Klausner R. D. Inhibition of transcriptional elongation by the VHL tumour suppressor protein. Science. 269:1995;1402-1406.
10. Fitch D. H. A., Thomas W. K. Evolution. Riddle D. L., Blumenthal T., Meyer B. J., Priess J. R. C. elegans II. 1997;Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
11. Foster K., Prowse A., van den Berg A., Fleming S., Hulsbeek M. M. F., Crossey P. A., Richards F. M., Cairns P., Affara N. A., Ferguson-Smith M. A., Buys C. H. C. M., Maher E. R. Somatic mutations of the von Hippel-Lindau disease tumor suppressor gene in nonfamilial clear cell renal carcinoma. Hum. Mol. Genet. 3:1994;2169-2173.
12. Gao J., Naglich J. G., Laidlaw J., Whaley J. M., Seizinger B. R., Kley N. Cloning and characterization of a mouse gene with homology to the human von Hippel-Lindau disease tumour suppressor gene: Implications for the potential organization of the human von Hippel-Lindau disease gene. Cancer Res. 55:1995;743-747.
13. Gnarra J. R., Tory K., Weng Y., Schmidt L., Wei M. H., Li H., Latif F., Liu S., Chen F., Duh F. M. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 7:1994;85-90.
14. Gnarra J. R., Zhou S., Merrill M. J., Wagner J., Krumm A., Papavassiliou E., Oldfield E. H., Klausner R. D., Klausner R. D. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the VHL tumour suppressor gene product. Proc. Natl. Acad. Sci. USA. 93:1996;10589-10594.
15. Herman J. G., Latif F., Weng Y., Lerman M. I., Zbar B., Liu S., Samid D., Duan D. S., Gnarra J. R., Linehan W. M. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. USA. 91:1994;9700-9704.
16. 19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation. Proc. Natl. Acad. Sci. USA. 95:1998;11661-11666.
17. Iliopoulos O., Jiang C., Levy A. P., Kaelin W. G., Goldberg M. A. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. USA. 93:1996;10595-10599.
18. Iliopoulos O., Kibel A., Gray S., Kaelin W. G. Tumour suppression by the human von Hippel-Lindau gene product. Nat. Med. 1:1995;822-826.
19. Kaelin W. G., Maher E. R. The VHL tumour suppressor gene paradigm. Trends Genet. 14:1998;423-425.
20. Kamura T., Koepp D. M., Conrad M. N., Skowyra D., Moreland R. J., Iliopoulos O., Lane W. S., Kaelin W. G. Jr., Elledge S. J., Conaway R. C., Harper J. W., Conaway J. W. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase. Science. 284:1999;657-661.
21. Kanno H., Kondo K., Ito S., Yamamoto I., Fujii S., Torigoe S., Sakai N., Hosaka M., Shuin T., Yao M. Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas. Cancer Res. 54:1994;4845-4847.
22. Kibel A., Iliopoulos O., DeCaprio J. D., Kaelin W. G. Binding of the von Hippel-Lindau tumour suppressor protein to elongin B and C. Science. 269:1995;1444-1446.
23. Kishida T., Stackhouse T. M., Chen F., Lerman M. I., Zbar B. Cellular proteins that bind the von Hippel-Lindau disease gene product: Mapping of binding domains and the effect of missense mutation. Cancer Res. 55:1995;4544-4548.
24. Koradi R., Billeter M., Wuthrich K. MOLMOL: A program for display and analysis of macromolecular structures. J. Mol. Graph. 14:1996;51-55.
25. Latif F., Tory K., Gnarra J., Yao M., Duh F. M., Orcutt M. L., Stackhouse T., Kuzmin I., Modi W., Geil L., Schmidt L., Zhou F., Li H., Wei M. W., Chen F., Choyke P., Walther M. M., Weng Y., Duan S. R., Dean M., Glavc D., Richards F. M., Crossey P. A., Ferguson-Smith M. A., LePaslier D., Chumakov I., Cohen D., Chinault A. C., Maher E. R., Linehan W. M., Zbar B., Lerman M. I. Identification of the von Hippel-Lindau disease tumour suppressor gene. Science. 260:1993;1317-1320.
26. Longergan K. M., Iliopoulos O., Ohh M., Kamura T., Conaway R. C., Weliky Conaway J., Kaelin W. G. Jr. Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2. Mol. Cell. Biol. 18:1998;732-741.
27. Maher E. R., Webster A. R., Richards F. M., Green J. S., Crossey P. A., Payne S. J., Moore A. T. Phenotypic expression in von Hippel-Lindau disease: Correlations with germline VHL gene mutations. J. Med. Genet. 33:1996;328-332.
28. Maher E. R., Yates J. R. W., Harries R., Benjamin C., Harris R., Moore A. T., Ferguson-Smith M. A. Clinical features and natural history of von Hippel-Lindau disease. Q. J. Med. 77:1990;1151-1163.
29. Maxwell P., Wiesener M., Chang G-W., Clifford S. C., Vaux E., Cockman M., Wykoff C., Pugh C., Maher E. R., Ratcliffe P. J. The von Hippel-Lindau gene product is necessary for oxygen-dependent proteolysis of hypoxia-inducible factor α subunits. Nature. 399:1999;271-275.
30. Mukhopadhyay D., Knebelmann B., Cohen H. T., Ananth S., Sukhatme V. P. The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol. Cell. Biol. 17:1997;5629-5639.
31. Neumann H. P. H., Eng C., Mulligan L. M., Glavac D., Ponder B. A. J., Maher E. R., Crossey P. A., Brauch H. Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia type 2. J. Am. Med. Assoc. 274:1995;1149-1151.
32. Ohh M., Yauch R. L., Longergan R. L., Whaley J. M., Stemmer-Rachamimov A. O., Louis D. N., Gavin B. J., Kley N., Kaelin W. G. Jr. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol. Cell. 1:1998;959-968.
33. Pause A., Lee S., Worrell R. A., Chen D. Y. T., Burgess W. H., Linehan W. M., Klausner R. D. The von Hippel-Lindau tumor suppressor product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc. Natl. Acad. Sci. USA. 94:1997;2156-2161.
34. Richards F. M., Payne S. J., Zbar B., Affara N. A., Ferguson-Smith M. A., Maher E. R. Molecular analysis of de novo germline mutations in the Von Hippel-Lindau disease gene. Hum. Mol. Genet. 4:1995;2139-2143.
35. Schoenfeld A., Davidowitz A. J., Burk R. D. A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor. Proc. Natl. Acad. Sci. USA. 95:1998;8817-8822.
36. Stebbins C. E., Kaelin W. G. Jr., Pavletich N. P. Structure of the VHL-ElonginC-elonginB complex: Implications for VHL tumor suppressor function. Science. 284:1999;455-461.
37. Takahata N., Satta Y. Evolution of the primate lineage leading to modern humans: Phylogenetic and demographic inferences from DNA sequences. Proc. Natl. Acad. Sci. USA. 94:1997;4811-4815.
38. Tamura K., Nei M. Estimation of the number of nucleotide substitutions in the control region of mitochondrial-DNA in humans and chimpanzees. Mol. Biol. Evol. 10:1993;512-526.
39. Tsuchiya H., Iseda T., Hino O. Identification of a novel protein (VBP-1) binding to the von Hippel-Lindau (VHL) tumour suppressor gene product. Cancer Res. 56:1996;2881-2885.
40. Vagner S., Gensac, Maret A., Bayard F., Amalric F., Prats H., Prats A. C. Alternative translation of human fibroblast growth factor 2 mRNA occurs by internal entry of ribosomes. Mol. Cell. Biol. 15:1995;35-44.
41. Woodward E. R., Eng C., McMahon R., Voutilainen R., Affara N. A., Ponder B. A. J., Maher E. R. Genetic predisposition to phaeochromocytoma: Analysis of candidate genes GDNF, RET and VHL. Hum. Mol. Genet. 7:1997;1051-1056.
42. Zbar B., Kishida T., Chen F., Schmidt L., Maher E. R., Richards F. M., Crossey P. A., Webster A. R., Affara N. A., Ferguson-Smith M. A., Brauch H., Galvac D., Neumann H. P. H., Tisherman S., Mulvihill J. J., Gross D., Shuin T., Whaley J., Seizinger B., Kley N., Oischwang S., Boisson C, Richard S., Lips C. H. M., Linehan W. M., Lerman M. Germline mutations in the von Hippel-Lindau (VHL) gene in families from North America, Europe, and Japan. Hum. Mutat. 8:1996;348-357.